Skip to main content
PharmAbcine Inc. logo

PharmAbcine Inc. — Investor Relations & Filings

Ticker · 208340 ISIN · KR7208340000 KO Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2022-03-16 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 208340

About PharmAbcine Inc.

http://pharmabcine.com/

PharmAbcine Inc. is a clinical-stage biotechnology company specializing in the development of fully human therapeutic monoclonal antibodies (mAbs). The company focuses on creating innovative treatments for diseases with high unmet medical needs, primarily in oncology, neovascular eye diseases, and other inflammatory and vascular disorders. Utilizing its proprietary human antibody library and discovery technologies, PharmAbcine advances a pipeline of next-generation IgG-based therapeutics. The company's mission is to contribute to human health by providing novel antibody-based drugs to patients.

Recent filings

Filing Released Lang Actions
사업보고서 (2021.12)
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive 'Consolidated Audit Report' (연결감사보고서) for PharmAbcine (주식회사 파멥신) covering the fiscal years 2020 and 2021. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. As it contains full financial statements and audit results for a specific period, it is classified as an Interim/Quarterly Report (IR) in the context of this database, as it serves as the primary financial reporting document for the period. FY 2021
2022-03-16 Korean
[기재정정]주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Correction Report' (정정신고) for a 'Notice of General Meeting of Shareholders' (주주총회소집공고). It contains detailed financial statements (balance sheets, income statements, cash flow statements) as part of the management reference materials for the upcoming shareholder meeting. Since this is a formal filing related to the materials provided for an AGM, it falls under the AGM-R category.
2022-03-16 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Correction Report' (정정신고) for a 'Proxy Solicitation & Information Statement' (의결권대리행사권유참고서류) filed by PharmAbcine. It contains detailed financial statements (balance sheets, income statements, cash flow statements) as part of the information provided to shareholders for the upcoming Annual General Meeting. Since the primary purpose of the document is to provide information to shareholders for voting purposes and it includes the proxy solicitation reference, it is classified as a Proxy Solicitation & Information Statement.
2022-03-16 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for PharmAbcine. It contains the meeting agenda, details on board activities, and financial statements (balance sheet, income statement) to be approved by shareholders. This type of document is a standard proxy statement/information circular provided to shareholders prior to an AGM to solicit votes and provide necessary background information. In the context of the provided categories, this fits the 'Proxy Solicitation & Information Statement' (PSI) classification.
2022-03-08 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit proxies from shareholders for an upcoming Annual General Meeting (AGM). It contains information about the meeting date, agenda items (such as approval of financial statements and director appointments), and proxy voting procedures. While it includes financial statements, these are provided as part of the proxy solicitation materials for the AGM, not as a standalone annual report or audit report. Therefore, it is classified as Proxy Solicitation & Information Statement.
2022-03-08 Korean
전환사채(해외전환사채포함)발행후만기전사채취득(제1회차)
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) regarding the 'Acquisition of Convertible Bonds before Maturity' (전환사채 발행후 만기전 사채 취득). This type of filing details the company's repurchase of its own debt instruments (convertible bonds) due to put-option exercises. Since this relates to the company's capital structure and financing activities, it falls under the 'Capital/Financing Update' category.
2022-02-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.